LINAGLIPTIN,METFORMIN

The combination of linagliptin and metformin is an oral medication approved by the Food and Drug Administration (FDA) on January 30, 2012. It is indicated for the treatment of type 2 diabetes to assist in blood sugar control.

Linagliptin and Metformin work together to improve blood sugar control in adults with type 2 diabetes mellitus. Doctors prescribe this combination when both medications are suitable for managing the condition along with diet and exercise.

The Linagliptin and Metformin combination is typically taken with food, either before or after a meal, to help reduce the risk of gastrointestinal side effects. It's important to follow the specific instructions provided by the healthcare provider regarding the timing of the dose.

Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them. Common side effects of Linagliptin and Metformin: Gastrointestinal issues (e.g., nausea, diarrhea, upset stomach) Headache Upper respiratory tract infections Cough Back pain Serious side effects of Linagliptin and Metformin: Lactic acidosis (a rare but serious condition, symptoms include muscle pain, weakness, and difficulty breathing) Hypoglycemia (low blood sugar, especially when taken with other diabetes medications) Severe allergic reactions (e.g., rash, itching, swelling) Kidney problems (e.g., changes in urination, swelling in feet or ankles) Liver problems (e.g., yellowing of the skin or eyes)

Lactic Acidosis Risk: Rare but serious and potentially life-threatening. Watch for symptoms like muscle pain, weakness, breathing difficulty, and abdominal discomfort. Monitor patients with kidney or liver issues, dehydration, or excessive alcohol use closely. Renal Impairment: Avoid use in patients with severe kidney impairment or acute kidney injury. Regularly monitor kidney function during treatment. Hypoglycemia: May cause low blood sugar, especially when combined with other diabetes medications (e.g., insulin or sulfonylureas). Recognise symptoms like shakiness, dizziness, and confusion. Hepatic Impairment: Use caution in patients with liver disease and monitor liver function periodically. Discontinue the drug if liver problems develop. Heart Failure: Exercise caution in patients with heart failure, as metformin may worsen the condition. Alcohol Use: Limit alcohol consumption, as excessive intake increases the risk of lactic acidosis and other complications.

Patients should inform their healthcare provider about any kidney or liver issues, as these medications require careful monitoring in such conditions. Healthcare providers should use caution when prescribing to elderly patients or those with a history of heart failure. Patients should regularly monitor their blood sugar levels, as the combination may increase the risk of hypoglycemia when used with other diabetes medications.

Follow your healthcare provider's instructions on dosage and timing to control your blood sugar effectively. Take the medication with food to minimise gastrointestinal side effects. Regularly monitor your blood sugar and watch for signs of low blood sugar, especially if you are also using other diabetes medications. Stay hydrated and limit alcohol intake to reduce the risk of serious side effects.

1. Haak T. Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes. https://pmc.ncbi.nlm.nih.gov/articles/PMC4284079/ 2. Mu Y, Pan C, Fan B, Hehnke U, Zhang X, Zhang X, Wang X, Liu J, Zhang Y, Du J, Ma J, Gong Y. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes. Diabetes Res Clin Pract. https://pubmed.ncbi.nlm.nih.gov/28088030/ 3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201281S014S018lbl.pdf 4. https://www.ema.europa.eu/en/documents/product-information/jentadueto-epar-product-information_en.pdf